Common use of Dose Clause in Contracts

Dose. Most agents are available in 0.5 M concentration. A single dose is typically 0.1 mmol/kg body mass leading to 10–20 ml injec- tion volume. Once the contrast agent and dose are set, they Recommendations for quality assurance A QA process should be in place using phantoms. This should be based on the study requirements and should demonstrate: • That the effects of regional variations in B1 homogeneity are small compared with the minimum change to be measured in patients • That the effects of any automated image enhancement processes do not affect quantification • That flip angles are calibrated correctly and the T1-weighted signal is stable over the acquisition period • Equivalence for different field strengths (if used) Contrast agents (dose, delivery, compounds, safety) Introduction Many low molecular weight (LMW) gadolinium-based con- trast agents have been approved for use in humans [36]. DCE-MRI use is technically “off-label” but similar in dose and delivery rate to clinical protocols. Some gadolinium- based contrast agents have significant liver uptake or protein binding that would need special protocols if used. It is unclear whether ionic and non-ionic agents produce differ- ent values of DCE-MRI parameters. Iron- and manganese- based agents are not recommended for DCE-MRI.